<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415324</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00168</org_study_id>
    <secondary_id>NCI-2009-00168</secondary_id>
    <secondary_id>PHI-55</secondary_id>
    <secondary_id>CDR0000518290</secondary_id>
    <secondary_id>PHI-55</secondary_id>
    <secondary_id>7427</secondary_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT00415324</nct_id>
  </id_info>
  <brief_title>Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of Halichondrin B Analog (E7389) in Combination With Cisplatin in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This trial is studying the side effects and best dose of eribulin mesylate and cisplatin in&#xD;
      treating patients with advanced solid tumors.Drugs used in chemotherapy, such as eribulin&#xD;
      mesylate and cisplatin, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving more than one drug (combination&#xD;
      chemotherapy) may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      I. To determine the maximum tolerated dose of E7389 and cisplatin in patients with advanced&#xD;
      solid tumors.&#xD;
&#xD;
      II. To determine the safety and toxicity of this regimen in these patients. III. To determine&#xD;
      the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      Outline: This is a multicenter, dose-escalation study. Patients receive eribulin mesylate IV&#xD;
      over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose determined by dose-limiting toxicity graded according to the NCI CTCAE version 4.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 8 weeks</time_frame>
    <description>Summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eribulin mesylate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>B1939</other_name>
    <other_name>E7389</other_name>
    <other_name>ER-086526</other_name>
    <other_name>halichrondrin B analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>correlative study</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>correlative study</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumor&#xD;
&#xD;
          -  Advanced disease, meeting both of the following criteria: Metastatic or unresectable&#xD;
             disease and standard curative or palliative measures do not exist or are no longer&#xD;
             effective.&#xD;
&#xD;
          -  No known active brain metastases&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following: ongoing or active infection, symptomatic congestive heart failure, unstable&#xD;
             angina pectoris, cardiac arrhythmia, psychiatric illness or social situation that&#xD;
             would limit study compliance.&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin&#xD;
             C).&#xD;
&#xD;
          -  No prior targeted therapy within the past 4 weeks&#xD;
&#xD;
          -  No prior immunotherapy within the past 4 weeks&#xD;
&#xD;
          -  No prior radiotherapy within the past 4 weeks.&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for advanced solid tumors.&#xD;
&#xD;
          -  No other concurrent investigational agents. Bisphosphonate therapy (e.g., pamidronate&#xD;
             or zolendronate) is not considered investigational therapy.&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients.&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies.&#xD;
&#xD;
          -  Tumor has spread to other parts of the body or cannot be removed by surgery.&#xD;
&#xD;
          -  More than 4 weeks since chemotherapy, biological therapy, or radiation therapy.&#xD;
&#xD;
          -  No more than two previous chemotherapy regimens for advanced solid tumor.&#xD;
&#xD;
          -  WBC &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mmÂ³&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  No prior cumulative cisplatin dose &gt; 300 mg/m^2&#xD;
&#xD;
          -  No preexisting neuropathy &lt;= grade 2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianna Koczywas</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California/Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

